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Summary In order to compare risk ofvarious internal organ cancers induced by ingested inorganic arsenic
and to assess the differences in risk between males and females, cancer potency indices were calculated using
mortality rates among residents in an endemic area of chronic arsenicism on the southwest coast of Taiwan,
and the Armitage-Doll multistage model. Based on a total of 898,806 person-years as well as 202 liver cancer,
304 lung cancer, 202 bladder cancer and 64 kidney cancer deaths, a significant dose-response relationship was
observed between arsenic level in drinking water and mortality of the cancers. The potency index of
developing cancer of the liver, lung, bladder and kidney due to an intake of 10 ig kgday of arsenic was
estimated as 4.3 x 10-3, 1.2 x 10-2, 1.2 x 10-2, and 4.2 x 10-3, respectively, for males; as well as 3.6 x 10-3,
1.3 x 10-2, 1.7 x 10-2, and 4.8 x 10-3, respectively, for females in the study area. The multiplicity of
inorganic arsenic-induced carcinogenicity without showing any organotropism deserves further investiga-
tion.
Arsenic is widely distributed in nature and mainly transport-
ed in the environment by water. The general population is
exposed to inorganic and organic arsenic through air, drink-
ing water, food, and beverages. Cigarette smokers may be
exposed to arsenic in tobacco, but the chemical form of
arsenic in the smoke remains unclear. Drugs containing inor-
ganic arsenic have been used for the treatment of leukaemia,
psoriasis, chronic bronchial asthma, and as a tonic. Workers
involved in the processing of copper, gold and lead ores as
well as in the using and producing arsenic-containing pes-
ticides may have high exposure to airborne arsenic (World
Health Organization, 1981).
The ingested or inhaled inorganic arsenic through medicin-
al, occupational and environmental exposures is well-docu-
mented as a human carcinogen of skin and lung (IARC,
1987). Using the prevalence of skin cancer among residents in
an endemic area of chronic arsenicism and an unexposed
control area (Tseng et al., 1968), U.S. Environmental Protec-
tion Agency made an estimation of potency index of develop-
ing skin cancer of 1.3 x 10' for an American male who is
exposed to 1 iLg kg day inorganic arsenic through drinking
water for a 76-year lifespan (Brown et al., 1989). Based on
the data from smelter workers in Anaconda, Montana
(Brown & Chu, 1983; Lee-Feldstein, 1983; Higgins et al.,
1982) and in Tacoma, Washington (Enterline & Marsh,
1980), we estimated a potency index of developing lung
cancer ranging from 4.6 x 10-3 to 2.4 x 10-2 for an
American male who is exposed to 1 gig kg day inorganic
arsenic through inhalation (Chen & Chen, 1991).
Significant associations between ingested arsenic and
malignant neoplasms of the liver, lung, bladder, and kidney
among residents in the endemic area of chronic arsenicism
were recently reported by us (Chen et al., 1985, 1986, and
1988a; Wu et al., 1989). Not only in the confined endemic
area, the elevated risk of internal organ cancers associated
with inorganic arsenic exposure through drinking water has
also been observed in 314 precincts and townships of Taiwan
(Chen & Wang, 1990). The specific aims of this study
included the comparison of cancer potency index of various
internal organs induced by ingested inorganic arsenic in
drinking water, and the evaluation of differences in the risk
between males and females. Based on the analysis of mor-
tality rates from cancers of the liver, lung, bladder and
kidney among residents in the endemic area of chronic
arsenicism using Armitage-Doll multistage models, we report
here a comparable carcinogenic potency of ingested arsenic
among cancers of the liver, lung, bladder and kidney within a
fourfold range of magnitude. The risk was practically iden-
tical for both males and females within a twofold range of
magnitude indicating no gender difference in arsenic-induced
carcinogenic responses.
Materials and methods
The study area and population have been described in our
previous report (Wu et al., 1989). Briefly, the study area is
limited to 42 southwestern coastal villages in six south-
western townships including Peimen, Hsuechia, Putai, Ichu,
Yensui and Hsiaying where the blackfoot disease is endemic.
Residents of the area have used water from artesian wells as
deep as 100 or more meters for more than 70 years because
of the high salinity of water from shallow wells which were
less than 10 metres in depth. Most residents are engaged in
farming, fishery and salt production. They live in a confined
area (30 km by 40 km) and share similar socioeconomic
status, living environments, lifestyles, dietary patterns and
even medical facilities. The only major difference in
environmental exposure among residents in the study area
appears to be the arsenic level in drinking water ranging
from 0.010 to 1.752ppm. In other words, such a circums-
tance provides a 'natural experiment' for the evaluation of
health hazards induced by ingested arsenic. The study
population was stratified into four groups according to the
median arsenic level of well water in each village, i.e.,
<0.10 ppm, 0.10-0.29 ppm, 0.30-0.59 ppm, and 0.60 or
more ppm. One village previously misclassified into the group
of 0.60 or more ppm was actually in the group of
0.10-0.29ppm. In total, there were 13 villages with median
arsenic levels <0.10 ppm, eight villages with levels 0.10-
0.29 ppm, 15 villages with levels 0.30-0.59 ppm, and six
villages with levels 0.60 or more ppm.
In Taiwan, any event of birth, death, marriage/divorce,
migration, education and employment is mandatorily
registered in household registration offices and annually
checked by their officers. Data of demographic and vital
statistics derived from the household registration system are
quite complete and accurate in Taiwan. The person-years
used as the denominators of mortality rates were derived
from demographic statistics of household registration offices.
Death certificates of residents who died from cancers during
the period from 1973 to 1986 were obtained from local
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household registration offices of studied townships. Causes of
death were reviewed and classified using the codes of the
Eight Revision of International Classification of Diseases,
Injuries and Causes of Death (World Health Organization,
1967), i.e., liver cancer (ICD 155), lung cancer (ICD 162),
bladder cancer (ICD 188), and kidney cancer (ICD 189.0).
As some study subjects died from more than one primary
cancers, all primary cancers enlisted in death certificates were
coded and analysed. Age-sex-specific mortality rates of each
disease were calculated for each of four groups with different
exposure levels to ingested arsenic.
In the absence of knowledge regarding the more specific
mechanism of arsenic action, the Armitage-Doll model (Doll,
1971) was considered adequate for the analysis of the
potency index of cancers due to arsenic intake. The model
was considered more informative than other non-biologically
based models for characterising cancer response in different
organs and gender, even though its biological basis is not
adequate. The Armitage-Doll model assumes that it takes k
transitions before a normal target cell becomes malignant
(i.e., at the kth stage). The dose-response model is obtained
by assuming that the transition rate from the (i-l)tb stage to
the it' stage is related to dose d by a, + bi x d if the stage is
dose-affected. Under the condition of lifetime exposure as in
the case considered in this paper, it can be shown that the
tumour incidence rate and age has a simple power relation-
ship I = c(d) x t', where c(d) is a function of dose d. The
model has been used to analyse data on cigarette smoking
habits and lung cancer among British physicians (Doll &
Peto, 1978). In the multistage model it is assumed that the
time from the formation of the malignant cell to the endpoint
of interest, i.e., incidence or mortality, is short. In the case of
incidence rates, it is assumed that the time from malignant
cell formation to clinical detection is short relative to the
time of formation of the malignant cell. Using mortality as
the endpoint increases the time from malignant cell to the
endpoint of interest by adding the survival time of the sub-
jects. The assumption was considered reasonable for liver
and lung cancers because of their short survival time. With
regards to bladder and kidney cancers, survival year was
subtracted from the age at death to estimate the age at
clinical detection of the diseases.
Although a model with high k value may imply prolifera-
tion of intermediate cells, high number of stages involved
may be a mathematical artifact of cell proliferation in the
framework of initiation-promotion-progression carcinogen-
esis. The Armitage-Doll model does not consider prolifera-
tion of cells at intermediate stages. Since cell proliferation is
believed to be an important step of carcinogenesis, it is not
appropriate to use the model to interpret mechanism of
carcinogenesis; it is more appropriate to consider the model
as describing risk pattern rather than describing mechanisms
of carcinogenesis. For this reason, we refrained from making
any mechanistic interpretation of the calculated results but
rather used the estimated k values as an indicator of risk
pattern with respect to age. This indicator, along with cancer
potential index prediction, were used for comparing risk
pattern and carcinogenic potency among different cancer
sites, and between males and females.
In this study, the age-specific mortality rate for a disease
was calculated based on the following model: I(t,d) = B(t)
+ H(t,d), where I(t,d) was the age and cause-specific mortal-
ity rate, B(t) was the background mortality rate, and H(t,d)
was the mortality rate due to the arsenic exposure at age t
and dose rate d. Under the Armitage-Doll multistage theory
of carcinogenesis, the background mortality B(t) has the
form c x tk, where c is a constant. However, in the calcula-
tion reported in this paper, the background cancer mortality
rate from the reference population, i.e., general population in
Taiwan, was used. Therefore, it was not necessary to assume
a mathematical form for the background rate. In the calcula-
tion, H(t,d) was assumed to have the mathematic form
(H(t,d) = f(d) X tk, where f(d) = a x d, a linear function, was
found adequate for our data. The addition of a quadratic
dose term to f(d) did not improve goodness of fit, using
likelihood ratio test at a significance level of P = 0.05. As
I(t,d) was equal to (c + a x d) x tk, both background and
arsenic-induced rates had the same power k. The parameters
a and k were estimated by the maximum likelihood method,
assuming that the number of cancer deaths was a Poisson
random variable with a mean equal to N x I(t,d), where N is
the person-years at risk. Although the standard errors for
parameters a and k could be provided if one were to use
asymptotic theory and information matrix derived from the
second derivatives of the likelihood function, they were not
calculated by this approach because of its notorious inac-
curacy and misleading results. A more appropriate approach
would be bootstrap simulation. However, it was considered
not worthwhile to do these extensive calculations because this
study was focused on comparing potency indices.
To compare the potential of arsenic in inducing various
internal organ cancers, a potency index defined as the excess
lifetime risk due to an intake of 10 tg kg day of arsenic was
calculated. The potency was thus defined to reflect incremen-
tal risk over background rather than relative risk which
could be inflated if background is small, e.g., kidney cancer
in females. Because two different models could both fit a
given data set adequately in the observed range of exposure,
but result in very different risk estimates when the models
were extrapolated to very low doses. The cancer potency
index was thus defined as excess risk calculated at
10,g kg day, a dose level corresponded approximately to
0.2 ppm of arsenic in drinking water which was within the
observed range of arsenic concentration in the study. The
calculated risk was thus less model-dependent. All the above-
mentioned analyses were carried out for males and females
separately. In the estimation of potency index, assumptions
were made that a male in average weighed 55 kg and drank
3.5 litres of water per day, a female weighed 50 kg and drank
2.0 litres of water per day according to a previous report.
Because only residents who had lived in the study area after
birth were included in this study, it was also assumed that
the arsenic intake for each person continued from the birth
to the end of the follow-up during 1973-1986. As the expo-
sure was continuous for lifetime, the linearity of the dose-
response model did not necessarily imply that the first stage
was affected by dose. It only implied, under the framework
of Armitage-Doll model, that one stage (any of the k stages)
was affected by the dose. Further information such as mig-
rants data which contained different exposure spans over
lifetime has to be obtained if the differentiation of dose-
affected stage will be made.
Results
There were 898,806 person-years including 467,173 person-
years for males and 431,633 person-years for females under
observation during the study period from 1973-1986. The
person-years stratified by sex, age and arsenic level in drink-
ing water are shown in Table I. Totally, there were 171,224,
87,826, 138,562, and 69,561 person-years, respectively, for
males resided in villages with arsenic levels in drinking water
of <0.10ppm, 0.10-0.29ppm, 0.30-0.59ppm and 0.60 or
more ppm. The corresponding person-years for females were
157,775, 81,032, 127,502, and 65,324, respectively.
In total, there were 140 male and 62 female liver cancer
deaths, 169 male and 135 female lung cancer deaths, 97 male
and 105 female bladder cancer deaths, as well as 30 male and
34 female kidney cancer deaths occurred during the study
period. The observed death numbers and mortality rates per
100,000 person-years by sex, age, and arsenic level in drink-
ing water are shown from Table II to Table V for cancers of
the liver, lung, bladder and kidney, respectively. Mortality
rates were found to increase significantly with age for all
cancers in both males and females. Generally speaking, males
had a higher mortality from liver cancer than females in
almost all age groups (Table II). Males had a higher mor-
tality from lung cancer than females at ages 50 or more, but
no consistent gender differences in lung cancer mortality were890 C.-J. CHEN et al.
Table I Person-years by age, sex and arsenic level in drinking water
Arsenic
level Age
Sex (ppm) <30 30-49 50-69 70+ Total
Male <0.10 111098 34315 21336 4475 171224
0.10-0.29 57894 17145 10617 2170 87826
0.30-0.59 91625 26558 16847 3532 138562
0.60+ 47614 13734 7242 971 69561
Total 308231 91752 56042 11143 467173
Female <0.10 98322 32536 21774 5143 157775
0.10-0.29 50569 15988 11480 2995 81032
0.30-0.59 79883 25387 18074 4158 127502
0.60+ 42729 13715 7896 984 65324
Total 271503 87626 59224 13280 431633
TableII Observeddeathnumberandmortalityrate(per 100,000)from
liver cancer by age, sex and arsenic level in drinking water
Arsenic Death number
level and Age
Sex (ppm) Mortality rate <30 30-4950-69 70+
Male <0.10 Number 1 13 20 4
Rate 0.9 37.9 93.7 89.4
0.10-0.29 Number 0 7 15 4
Rate 0.0 40.8 141.3 184.3
0.30-0.59 Number 3 11 26 6
Rate 3.3 41.4 154.3 169.8
0.60+ Number 1 11 17 1
Rate 2.1 80.1 234.7 103.0
Female <0.10 Number 0 3 9 4
Rate 0.0 9.3 41.3 77.8
0.10-0.29 Number 0 2 8 2
Rate 0.0 12.5 69.7 66.8
0.30-0.59 Number 1 7 10 3
Rate 1.3 27.6 55.3 72.1
0.60+ Number 0 4 7 2
Rate 0.0 29.2 88.7 203.3
Table III Observed death number and mortality rate (per 100,000)
from lung cancer by age, sex and arsenic level in drinking water
Arsenic Death number
level and Age
Sex (ppm) Mortality rate <30 30-4950-69 70+
Male <0.10 Number 1 3 20 14
Rate 0.9 8.7 93.7 312.8
0.10-0.29 Number 0 2 13 11
Rate 0.0 11.7 122.4 506.9
0.30-0.59 Number 1 11 40 16
Rate 1.1 41.4 237.4 452.9
0.60+ Number 1 4 26 6
Rate 2.1 29.1 359.0 617.9
Female <0.10 Number 2 5 19 5
Rate 2.0 15.5 87.3 97.2
0.10-0.29 Number 0 6 13 3
Rate 0.0 37.5 113.2 100.2
0.30-0.59 Number 0 7 28 10
Rate 0.0 27.6 154.9 240.4
0.60+ Number 0 7 26 4
Rate 0.0 51.0 329.3 406.5
observed for younger age groups (Table III). Males and
females had similar age-specific mortality rates from bladder
and kidney cancers as shown in Table IV and Table V,
respectively. Significant dose-response relationships were
observed between the ingested arsenic level and mortality
from cancer of the liver, lung, bladder and kidney in most
age groups of both males and females.
In the analysis by Armitage-Doll multistage models, the
goodness of fit between observed and predicted mortality
rates indicated the applicability of the models to the mor-
tality rates of these four internal organ cancers. The max-
imum likelihood estimates of parameters of multistage
models and cancer potency index associated with ingested
arsenic are shown in Table VI. The stage parameter k was
Table IV Observed death number and mortality rate (per 100,000)
from bladder cancer by age, sex and arsenic level in drinking water
Arsenic Death number
level and Age
Sex (ppm) Mortality rate <30 30-4950-69 70+
Male <0.10 Number 0 1 8 10
Rate 0.0 2.9 37.5 223.5
0.10-0.29 Number 0 0 6 2
Rate 0.0 0.0 56.5 92.2
0.30-0.59 Number 0 5 22 11
Rate 0.0 18.8 130.6 311.4
0.60+ Number 0 4 19 9
Rate 0.0 29.1 262.4 926.9
Female <0.10 Number 0 3 11 9
Rate 0.0 9.3 50.5 175.0
0.10-0.29 Number 0 0 8 2
Rate 0.0 0.0 69.7 66.8
0.30-0.59 Number 0 0 22 15
Rate 0.0 0.0 121.7 360.7
0.60+ Number 0 2 27 6
Rate 0.0 14.6 341.9 609.8
TableV Observed deathnumberandmortality rate(per 100,000)from
kidney cancer by age, sex and arsenic level in drinking water
Arsenic Death number
level and Age
Sex (ppm) Mortality rate <30 30-49 50-69 70+
Male <0.10 Number 0 0 4 3
Rate 0.0 0.0 18.7 67.0
0.10-0.29 Number 0 0 2 1
Rate 0.0 0.0 18.8 46.1
0.30-0.59 Number 0 2 9 2
Rate 0.0 7.5 53.4 56.6
0.60+ Number 0 0 3 4
Rate 0.0 0.0 41.4 411.9
Female <0.10 Number 0 0 1 1
Rate 0.0 0.0 4.6 19.4
0.10-0.29 Number 0 1 3 1
Rate 0.0 6.3 26.1 33.4
0.30-0.59 Number 0 2 7 5
Rate 0.0 7.9 38.7 120.2
0.60+ Number 0 4 6 3
Rate 0.0 29.2 76.0 304.9
Table VI Parameters of multistage models and cancer potency
index
Parametersa
Disease Sex a k Potency indexb
Liver cancer Male 3.3E-8 2.6 0.0043
Female 1.OE-8 2.8 0.0036
Lung cancer Male 2.2E-10 4.0 0.012
Female 2.2E-9 3.4 0.013
Bladder cancer Male 6.3E-11 4.5 0.012
Female 1.4E-11 4.9 0.017
Kidney cancer Male l.lE-12 5.2 0.0042
Female 2.4E-9 3.3 0.0048
aa: Potency parameter, E-n = l0-; k: stage parameter. bExcess
lifetime risk due to an intake of 101.g kg day of arsenic.
found to range from 2.6 to 5.2 for arsenic-induced cancers.
Liver cancer had lowest k value in both males and females.
The lifetime risk of devloping cancer of the liver, lung,
bladder and kidney due to an intake of 10fg kg day of
arsenic was 4.3 x 10-3, 1.2 x 10-2, 1.2 x 10-2, and 4.2 x
10-3, respectively, for males as well as 3.6 x 10-3, 1.3 x 10-2,
1.7 x 10-2, and 4.8 x 10-3, respectively, for females in the
study area. The risk for males and females was practically
identical within a twofold range of magnitude indicating no
gender difference in arsenic-induced carcinogenic responses.
Furthermore, the potency was also comparable among
cancers of four different internal organs within a fourfold
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Discussion
Arsenic is a well-documented human carcinogen of skin and
lung (IARC, 1987) and is known to be associated with
cancers of other sites as well, most notably those of the
digestive and urinary systems (Gibb & Chen, 1989). We
reported a significantly increased mortality from cancers of
the liver, lung, bladder, kidney and skin among residents in
the endemic area of blackfoot disease, and a dose-response
relationship between age-standardised mortality of these
cancers and endemicity of blackfoot disease (Chen et al.,
1985). A case-control study conducted in this area showed a
significant association between duration of consuming high-
arsenic artesian well water and cancers of the liver, lung and
bladder (Chen et al., 1986). A dose-response relationship
between arsenic level in drinking water and age-adjusted
mortality from cancers was observed in the blackfoot disease-
endemic area (Chen et al., 1988a; Wu et al., 1989). Such
associations were also observed in an island-wide ecological
correlation study in which 314 precincts and townships were
included (Chen & Wang, 1990). Patients of the blackfoot
disease, an endemic peripheral arterial disease associated with
long-term exposures to high-arsenic artesian well water, also
had a significantly increased mortality from cancers of the
liver, lung, bladder and kidney (Chen et al., 1988b). The
consistent results of these studies suggest arsenic is a human
carcinogen of the liver, bladder and kidney in addition to
lung and skin.
In our previous reports, dose-response relations between
ingested arsenic and various cancers were analysed using
standardised mortality ratios, cumulative mortality rates and
age-adjusted mortality rates without considering background
mortality rates of the general population. In this study, we
further characterised cancer risk induced by ingested arsenic
using Armitage-Doll multistage models in order to make
comparisons among different cancer sites, and between males
and females. In the absence ofknowledge regarding the more
specific mechanism of arsenic action, the model was con-
sidered more informative than other non-biologically based
models for characterising cancer response in different organs
and gender. The cancer potency index was defined to reflect
incremental risk over background rather than relativer risk
which could be inflated if background was small, e.g., kidney
cancer in females.
It is inevitable that any risk assessment is always
associated with uncertainties to some degree. The risk esti-
mates in this study may be somewhat underestimated because
it was assumed that the arsenic intake for each person con-
tinued from the birth to the end of the follow-up during
1973-1986. Tap water system was first implemented in study
area in 1956 but not available in most study villages in 1960s.
However, tap water was available for almost 75% of resi-
dents in the area in 1970s. In other words, some residents
may no longer be exposed to arsenic through drinking water
after 1970. If the latent period of studied cancers is greater
than 10 years, the underestimation is expected to be insig-
nificant. However, this assumption may not be valid if
arsenic stimulates the proliferation of the existing pre-
neoplastic cells or the progression of pre-neoplastic cells into
malignant cells. If arsenic does act in such a manner, the risk
will be underestimated, especially for older persons who are
more likely to possess more pre-neoplastic cells than the
younger ones.
Based on the lung cancer risk induced by inhaled arsenic
among two cohorts of copper smelter workers, it has been
reported that arsenic appears to exert a definite effect on a
late stage of the carcinogenic process, although an additional
effect at the initial stage cannot be ruled out (Brown & Chu,
1983; Mazumdar et al., 1989). Recently, it has been hypo-
thesised that arsenic may act specifically in the progression
phase of carcinogenicity because arsenic is not an initiator or
tumour promoter in two-stage models of animal carcino-
genesis but has an ability to induce gene amplification instead
of gene mutation (Lee et al., 1988). Analysis of cancer
mortality experienced by migrants who moved in and out of
the endemic area of chronic arsenicism at different ages may
provide best data for evaluating the hypothesis.
On the other hand, the risk estimates may also be some-
what overestimated because inorganic arsenic intakes from
sources other than drinking water were not included in the
calculation. As high-arsenic drinking water was the major
source of arsenic exposure and study subjects were living in
similar environments and lifestyles, such an overestimation
may not be significant.
In this study, we observed a comparable excess risk
induced by ingested arsenic for four different internal organs
including the liver, lung, bladder and kidney. The multiplicity
of arsenic-induced carcinogenicity without showing any
organotropism is noteworthy. Pharmacokinetic data in
animal studies show arsenic concentrations in lung, liver and
kidney tissues are comparable through ingestion or inhala-
tion (Vahter & Norin, 1980). Although the arsenic concentra-
tion of the bladder is not reported, urine excretion is the
major route of arsenic elimination (Buchet et al., 1981) sug-
gesting that the bladder is a target organ for arsenic assault.
The data of pharmacokinetic parameters including partition
coefficients of tissues and blood as well as tissue concentra-
tion over time are useful for improving the risk assess-
ment.
From the viewpoint of cancer risk assessment, the utmost
importance is the understanding of the mechanism of action.
It is essential to identify the stage(s) in the multistep car-
cinogenesis that is affected by arsenic. There are considerable
evidences indicating the multistage nature of carcinogenesis
(Weinstein, 1988), and multiple changes in oncogenes and
tumour suppressor genes have been documented to be
involved in the development ofcommon cancers such as lung
and colorectal cancers (Weston et al., 1989; Vogelstein et al.,
1990). Such gene changes, especially the loss of tumour supp-
ressor genes at late stages resulting from increased chromo-
somal aberrations and sister chromatid exchanges, could also
be involved in the arsenic-induced cancers of the lung, liver,
bladder and kidney. It is important to elucidate whether the
changes occur and are consistent for different arsenic-induced
cancers as well as to examine whether the changes are similar
to those induced by other carcinogens.
On the other hand, arsenic could be a human carcinogen
without having any genotoxic effect the same as sodium
saccharin and asbestos. It might induce human cancers
through the induction of cell proliferation. If this is the case,
the cancer dose-response models incorporating clonal expan-
sion (Chen & Moini 1990; Moolgavkar & Venzon 1979;
Moolgarvkar & Knudson 1981; Chen & Farland 1991; Tan
& Chen 1991; Yang & Chen 1991) should be used in the risk
assessment of arsenic. Further studies on the carcinogenic
mechanism of arsenic are needed for a better assessment of
its risk.
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